https://www.selleckchem.com/products/bgb-290.html
015), and type of palliative first-line treatment (OS 2 P0.001) significantly affected overall survival after disease recurrence in PDAC. Determining tumour subgroups using prognostic factors may be helpful to stratify PDAC patients for future clinical trials. In case of disease recurrence, the site of relapse may have a prognostic impact on subsequent survival. Further investigations are needed to identify differences in tumour biology, reflecting relapse patterns and the differing survival of PDAC patients. Determining tumour subg
Aimer
Commentaire
Partagez
